Although the methods by which leukemia is classified have been improved for effective therapies, leukemia patients occasionally exhibit diverse, sometimes unpredictable, responses to treatment. Consequently, these patients also evidence individually different clinical courses when administered with anti-leukemia drugs. In order to find new, more precise molecular markers for leukemia classification, we have analyzed the gene expression profiles from 65 diagnostic bone marrow specimens of adult patients with AML, ALL, CML or CLL by using high-throughput DNA microarrays harboring approximately 8300 unique human genes or expression sequence tags. In the present study, we identified a group of leukemia-specific genes, which manifest gene expression profiles distinctly representative of normal bone marrow samples, as determined by a significance analysis of microarray (SAM) and GeneSpring 6.1 programs. We also determined the minimal number of genes showing a difference between acute and chronic leukemia patient groups. Furthermore, the unsupervised cluster analysis revealed a gene subset which can be used to distinguish between AML, ALL, CML and CLL patient groups, based on expression signatures. The expression levels of differentially regulated genes were verified via the principle component analysis (PCA). Our results may provide a novel set of molecular criteria for the classification of leukemia patients, and may also facilitate effects to discovery new targets, allowing for more effective treatment of leukemia patients.
|Number of pages||8|
|Journal||International journal of oncology|
|Publication status||Published - 2006 Jul|
- DNA microarray
ASJC Scopus subject areas
- Cancer Research